Delivery Order SPE2DR25D2100-SPE2DR26FA0EW
Award Date 11/20/25
Potential Completion Date 11/21/25
Potential Value $30K
Federal Agency
Awardee
Ultimate Awardee
Not listed PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Defense Logistics Agency awarded a delivery order valued at $37,698.62 to AmerisourceBergen Drug Corp for the supply of HUMIRA (Adalimumab) Pen 40 mg/0.4 mL, a biologic pharmaceutical used to treat autoimmune conditions. This firm fixed-price delivery order was competitively awarded without set-aside designation and has an ultimate completion date of May 21, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on September 29, 2025, for the supply of HUMIRA Pen 40 mg/0.8 mL, a biologic medication commonly used to treat autoimmune conditions. This firm fixed-price delivery order, valued at $1,405.04, represents a single transaction under the company's larger indefinite delivery contract (IDC) with DLA Troop Support Medical (SPE2DX), which is valued at $999.99 million and extends through December 2026. The...
- The Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of HUMIRA (adalimumab) Pen 40 mg/0.4 mL, a biologic immunosuppressant medication. This firm fixed-price delivery order, valued at $57,804.94, represents a non-competitive award under a larger contract vehicle and is scheduled for completion by August 8, 2025. The pharmaceutical product will be delivered to AmerisourceBergen's facility in Conshohocken,...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on October 22, 2025, for the supply of HUMIRA (CF) Pen 40 mg/0.4 mls, a biologic medication used to treat autoimmune conditions. The contract is valued at $6,817.16 and is classified as a firm fixed-price delivery order with an ultimate completion date of October 23, 2025. The award uses no set-aside designation, indicating it was competitively awarded. AmerisourceBergen, headquartered in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order valued at $1,953.33 to AmerisourceBergen Drug Corp for HUMIRA (adalimumab) Pen 40 mg/0.4 mL, a biologic immunosuppressant medication used to treat autoimmune conditions. The contract is a firm fixed-price delivery order with an ultimate completion date of September 24, 2025, and was awarded on a competitive, non-set-aside basis. Performance will take place at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania, where the...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on November 12, 2025, for the supply of Humira (Adalimumab) prefilled pens at 40 mg/0.4 mL, a biologic medication used to treat autoimmune conditions. This firm fixed-price delivery order, valued at $5,264.52, represents a non-competitive set-aside award and is scheduled for completion by November 13, 2025. The order will be fulfilled from AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the...
- The Defense Logistics Agency awarded a $3,715.82 delivery order to AmerisourceBergen Drug Corp on October 27, 2025, for the supply of HUMIRA (Adalimumab) CF Pen 40 mg/0.4 mL. This competitively awarded, firm fixed-price contract is set to conclude on October 28, 2025, with performance executed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The delivery order represents a single transaction under AmerisourceBergen's larger pharmaceutical supply relationship with the...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $21,573.54 to AmerisourceBergen Drug Corp for the supply of HUMIRA (Adalimumab) CF Pen 40 mg/0.4 mL, a biologic medication used to treat autoimmune conditions. This non-set-aside contract employs firm fixed price terms with a completion date of June 20, 2025, and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency has awarded a delivery order valued at $2,022.32 to AmerisourceBergen Drug Corp for the supply of HUMIRA (Adalimumab) Pen 40 mg/0.4 mL, a biologic medication commonly used to treat autoimmune and inflammatory conditions. This competitively awarded, firm fixed-price delivery order was issued on November 20, 2025, with an ultimate completion date of November 21, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on November 3, 2025, for the supply of HUMIRA Pen 40 mg/0.8 mls, a biologic medication used to treat inflammatory conditions. This firm fixed-price delivery order, valued at $1,575.72, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, a $999.99 billion prime vendor agreement running through December 2026. The award was made on a...